To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 2/23 cls
Aradigm (ARDM) Merriman Curhan Ford E. Russell McAllister New Buy 13% $1.46
McAllister set a $4-$5 fair value range. He believes that ARDM’s product candidates and existing partnerships are undervalued. The company’s AERx insulin Diabetes Management System (iDMS) is in Phase III testing for Type I and Type II diabetes with data expected in 2009. Novo Nordisk (NVO) has worldwide rights.
Arena (ARNA) Lazard Matthew Osborne New Buy -1% $13.71
Osborne set an $18 target. He expects a data safety monitoring board (DSMB) to recommend continuing the Phase III BLOOM trial of lorcaserin to treat obesity in 3Q07.
BioTie (HSE:BTH1V) Nomura Chris Redhead New Buy -2% €0.99
Redhead thinks BTH1V

Read the full 1301 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers